HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

## CodeSystem: ESMO-MCBS Evaluation Form

Official URL: https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form | Version: 0.1.0
Active as of 2026-05-21 | Computable Name: EsmoMcbsEvaluationForm

The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale

This Code system is referenced in the content logical definition of the following value sets:

- EsmoMcbsEvaluationForm

This code system `https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` defines the following codes:

Code | Display
ST-1a | Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies
ST-1b | Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting
ST-2a | Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS
ST-2b | Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS
ST-2c | Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
ST-3 | Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR
HM-1a | Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies
HM-1b | Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies
HM-2a | Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS
HM-2b | Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS
HM-2c | Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
HM-3 | Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR